FABP4 and neoplasm: In the field of tumor therapy, small-molecule inhibitors targeting FABP4 (such as BMS-309403) can inhibit tumor angiogenesis and epithelial-mesenchymal transition (EMT), and their synergistic effects with chemotherapeutic drugs have entered preclinical research stages[29].